Research – Patz

Ned Patz

Dr. Ned Patz and his team of physicians and scientists are working to better understand early cancer detection and novel treatment strategies.

Most recently, Dr. Patz’s lab developed the first human-derived antibody for the treatment of lung cancer. Using an innovative strategy that explored the response of lung cancer patients with early-stage non-small cell lung cancer (NSCLC) who never developed metastatic disease, they discovered that some patients had an antibody that blocks an essential tumor cell protective protein called complement factor H (CFH). This anti-CFH antibody caused tumor cell death through activation of a biologic cascade and adaptive immune response in patients with lung cancer.

Dr. Patz’s innovative research in now in a Phase 1 clinical trial for patients with advanced stage NSCLC. This trial is open for enrollment, and listed at ClinicalTrial.gov.

For addition information about the Patz laboratory, please visit his website.